

Chapter 56

Bullous Pemphigoid

Donna A. Culton, Zhi Liu, & Luis A. Diaz

REFERENCES

1. Lever WF: Pemphigus. *Medicine (Baltimore)* **32**(1):1, 1953
2. Beutner EH et al: Autoantibodies in pemphigus vulgaris: Response to an intercellular substance of epidermis. *JAMA* **192**:682, 1965
3. Jordon RE et al: Basement zone antibodies in bullous pemphigoid. *JAMA* **200**(9):751, 1967
4. Gudi VS et al: Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland. *Br J Dermatol* **153**(2):424, 2005
5. Amos B et al: Bullous pemphigoid in infancy: Case report and literature review. *Pediatr Dermatol* **15**(2):108, 1998
6. Fisler RE et al: Childhood bullous pemphigoid: A clinicopathologic study and review of the literature. *Am J Dermatopathol* **25**(3):183, 2003
7. Gajic-Veljic M, Nikolic M, Medenica L: Juvenile bullous pemphigoid: The presentation and follow-up of six cases. *J Eur Acad Dermatol Venereol* **24**(1):69, 2010
8. Trueb RM et al: Childhood bullous pemphigoid: Report of a case with characterization of the targeted antigens. *J Am Acad Dermatol* **40**(2 Pt 2):338, 1999
9. Bernard P et al: Survival prognosis in pemphigoid. A cohort analysis of 78 patients. *Ann Dermatol Venereol* **122**(11-12):751, 1995
10. Zillikens D et al: Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. *Arch Dermatol* **131**(8):957, 1995
11. Bernard P et al: Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. *Arch Dermatol* **131**(1):48, 1995
12. Langan SM et al: Bullous pemphigoid and pemphigus vulgaris—Incidence and mortality in the UK: Population based cohort study. *BMJ* **337**:a180, 2008
13. Mutasim DF et al: A pool of bullous pemphigoid antigen(s) is intracellular and associated with the basal cell cytoskeleton-hemidesmosome complex. *J Invest Dermatol* **84**(1):47, 1985
14. Stanley JR: Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion. *Adv Immunol* **53**:291, 1993
15. Stanley JR et al: Characterization of bullous pemphigoid antigen: A unique basement membrane protein of stratified squamous epithelia. *Cell* **24**(3):897, 1981
16. Thoma-Uszynski S et al: BP230- and BP180-specific auto-antibodies in bullous pemphigoid. *J Invest Dermatol* **122**(6):1413, 2004
17. Yoshida M et al: Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. *J Dermatol Sci* **41**(1):21, 2006
18. Green KJ et al: Comparative structural analysis of desmoplakin, bullous pemphigoid antigen and plectin: Members of a new gene family involved in organization of intermediate filaments. *Int J Biol Macromol* **14**(3):145, 1992
19. Stanley JR et al: Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies. *J Clin Invest* **82**(6):1864, 1988
20. Tanaka T et al: Production of rabbit antibodies against carboxy-terminal epitopes encoded by bullous pemphigoid cDNA. *J Invest Dermatol* **94**(5):617, 1990
21. Guo L et al: Gene targeting of BPAG1: Abnormalities in mechanical strength and cell migration in stratified epithelia and neurologic degeneration. *Cell* **81**(2):233, 1995
22. Brown A et al: The mouse dystonia musculorum gene is a neural isoform of bullous pemphigoid antigen 1. *Nat Genet* **10**(3):301, 1995
23. Yang Y et al: An essential cytoskeletal linker protein connecting actin microfilaments to intermediate filaments. *Cell* **86**(4):655, 1996
24. Haase C et al: Detection of IgG autoantibodies in the sera of patients with bullous and gestational pemphigoid: ELISA studies utilizing a baculovirus-encoded form of bullous pemphigoid antigen 2. *J Invest Dermatol* **110**(3):282, 1998

25. Labib RS et al: Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. *J Immunol* **136**(4):1231, 1986
26. Zillikens D et al: A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. *J Invest Dermatol* **109**(5):679, 1997
27. Bedane C et al: Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: Evidence that BP180 spans the lamina lucida. *J Invest Dermatol* **108**(6):901, 1997
28. Diaz LA et al: Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. *J Clin Invest* **86**(4):1088, 1990
29. Giudice GJ, Emery DJ, Diaz LA: Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. *J Invest Dermatol* **99**(3):243, 1992
30. Giudice GJ et al: Identification of two collagen domains within the bullous pemphigoid autoantigen, BP180. *J Clin Invest* **87**(2):734, 1991
31. Hopkinson SB, Riddelle KS, Jones JC: Cytoplasmic domain of the 180-kD bullous pemphigoid antigen, a hemidesmosomal component: Molecular and cell biologic characterization. *J Invest Dermatol* **99**(3):264, 1992
32. Borradori L et al: The localization of bullous pemphigoid antigen 180 (BP180) in hemidesmosomes is mediated by its cytoplasmic domain and seems to be regulated by the beta4 integrin subunit. *J Cell Biol* **136**(6):1333, 1997
33. Ishiko A et al: Human autoantibodies against the 230-kD bullous pemphigoid antigen (BPAG1) bind only to the intracellular domain of the hemidesmosome, whereas those against the 180-kD bullous pemphigoid antigen (BPAG2) bind along the plasma membrane of the hemidesmosome in normal human and swine skin. *J Clin Invest* **91**(4):1608, 1993
34. Masunaga T et al: The extracellular domain of BPAG2 localizes to anchoring filaments and its carboxyl terminus extends to the lamina densa of normal human epidermal basement membrane. *J Invest Dermatol* **109**(2):200, 1997
35. Giudice GJ et al: Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. *J Immunol* **151**(10):5742, 1993
36. Zillikens D et al: Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. *J Invest Dermatol* **109**(4):573, 1997
37. Sakuma-Oyama Y et al: Evaluation of a BP180-NC16a enzyme-linked immunosorbent assay in the initial diagnosis of bullous pemphigoid. *Br J Dermatol* **151**(1):126, 2004
38. Schmidt E et al: Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. *Arch Dermatol* **136**(2):174, 2000
39. Tsuji-Abe Y et al: Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. *J Dermatol Sci* **37**(3):145, 2005
40. Hofmann S et al: Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH₂- and COOH-terminal regions of the BP180 ectodomain. *J Invest Dermatol* **119**(5):1065, 2002
41. Jonkman MF et al: 180-kD bullous pemphigoid antigen (BP180) is deficient in generalized atrophic benign epidermolysis bullosa. *J Clin Invest* **95**(3):1345, 1995
42. McGrath JA et al: A homozygous deletion mutation in the gene encoding the 180-kDa bullous pemphigoid antigen (BPAG2) in a family with generalized atrophic benign epidermolysis bullosa. *J Invest Dermatol* **106**(4):771, 1996
43. Fine JD et al: The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. *J Am Acad Dermatol* **58**:931, 2008
44. Christophoridis S et al: IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis. *Br J Dermatol* **143**(2):349, 2000
45. Dimson OG et al: Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. *J Invest Dermatol* **120**(5):784, 2003
46. Dopp R et al: IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: Serum levels of these immunoglobulins reflect disease activity. *J Am Acad Dermatol* **42**(4):577, 2000
47. Borrego L et al: Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins. *Am J Pathol* **148**(3):897, 1996

48. Czech W et al: Granulocyte activation in bullous diseases: Release of granular proteins in bullous pemphigoid and pemphigus vulgaris. *J Am Acad Dermatol* **29**(2 Pt 1):210, 1993
49. Dvorak AM et al: Bullous pemphigoid, an ultra-structural study of the inflammatory response: Eosinophil, basophil and mast cell granule changes in multiple biopsies from one patient. *J Invest Dermatol* **78**(2):91, 1982
50. Wintroub BU et al: Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid. *N Engl J Med* **298**(8):417, 1978
51. Baba T et al: An eosinophil chemotactic factor present in blister fluids of bullous pemphigoid patients. *J Immunol* **116**(1):112, 1976
52. D'Auria L, Cordiali Fei P, Ameglio F: Cytokines and bullous pemphigoid. *Eur Cytokine Netw* **10**(2):123, 1999
53. Diaz-Perez JL, Jordon RE: The complement system in bullous pemphigoid. IV. Chemotactic activity in blister fluid. *Clin Immunol Immunopathol* **5**(3):360, 1976
54. Katayama I, Doi T, Nishioka K: High histamine level in the blister fluid of bullous pemphigoid. *Arch Dermatol Res* **276**(2):126, 1984
55. Kawana S, Ueno A, Nishiyama S: Increased levels of immunoreactive leukotriene B4 in blister fluids of bullous pemphigoid patients and effects of a selective 5-lipoxygenase inhibitor on experimental skin lesions. *Acta Derm Venereol* **70**(4):281, 1990
56. Schmidt E et al: Elevated levels of interleukin-8 in blister fluid of bullous pemphigoid compared with suction blisters of healthy control subjects. *J Am Acad Dermatol* **34**(2 Pt 1):310, 1996
57. Schmidt E et al: Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. *Arch Dermatol Res* **288**(7):353, 1996
58. Schmidt E et al: Detection of IL-1 alpha, IL-1 beta and IL-1 receptor antagonist in blister fluid of bullous pemphigoid. *J Dermatol Sci* **11**(2):142, 1996
59. Wakugawa M et al: Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: Correlation with tissue eosinophilia. *Br J Dermatol* **143**(1):112, 2000
60. Baird J et al: mRNA for tissue-type plasminogen activator is present in lesional epidermis from patients with psoriasis, pemphigus, or bullous pemphigoid, but is not detected in normal epidermis. *J Invest Dermatol* **95**(5):548, 1990
61. Gissler HM, Simon MM, Kramer MD: Enhanced association of plasminogen/plasmin with lesional epidermis of bullous pemphigoid. *Br J Dermatol* **127**(3):272, 1992
62. Kramer MD, Reinartz J: The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin. *J Clin Invest* **92**(2):978, 1993
63. Lauharanta J, Salonen EM, Vaeheri A: Plasmin-like proteinase associated with high molecular weight complexes in blister fluid of bullous pemphigoid. *Acta Derm Venereol* **69**(6):527, 1989
64. Oikarinen AI et al: Demonstration of collagenase and elastase activities in the blister fluids from bullous skin diseases. Comparison between dermatitis herpetiformis and bullous pemphigoid. *J Invest Dermatol* **81**(3):261, 1983
65. Schaefer BM et al: Plasminogen activation in bullous pemphigoid immunohistology reveals urokinase type plasminogen activator, its receptor and plasminogen activator inhibitor type-2 in lesional epidermis. *Autoimmunity* **23**(3):155, 1996
66. Stahle-Backdahl M et al: 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. *J Clin Invest* **93**(5):2022, 1994
67. Verraes S et al: Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. *J Invest Dermatol* **117**(5):1091, 2001
68. Gammon WR et al: An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement. *J Invest Dermatol* **78**(4):285, 1982
69. Sitaru C et al: Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. *J Invest Dermatol* **118**(4):664, 2002
70. Liu Z et al: A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. *J Clin Invest* **92**(5):2480, 1993
71. Chen R et al: Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. *J Clin Invest* **108**(8):1151, 2001
72. Liu Z et al: The role of complement in experimental bullous pemphigoid. *J Clin Invest* **95**(4):1539, 1995

73. Liu Z et al: A major role for neutrophils in experimental bullous pemphigoid. *J Clin Invest* **100**(5):1256, 1997
74. Nelson KC et al: Role of different pathways of the complement cascade in experimental bullous pemphigoid. *J Clin Invest* **116**(11):2892, 2006
75. Liu Z: Bullous pemphigoid: Using animal models to study the immunopathology. *J Investig Dermatol Symp Proc* **9**(1):41, 2004
76. Liu Z et al: Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. *J Clin Invest* **115**(4):879, 2005
77. Liu Z et al: A critical role for neutrophil elastase in experimental bullous pemphigoid. *J Clin Invest* **105**(1):113, 2000
78. Liu Z et al: Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. *J Exp Med* **188**(3):475, 1998
79. Liu Z et al: The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. *Cell* **102**(5):647, 2000
80. Liu Z et al: Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. *J Autoimmun* **31**(4):331, 2008
81. Nishie W et al: Humanization of autoantigen. *Nat Med* **13**(3):378, 2007
82. Fairley JA et al: A pathogenic role for IgE in autoimmunity: Bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. *J Invest Dermatol* **127**(11):2605, 2007
83. Zone JJ et al: IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. *J Invest Dermatol* **127**(5):1167, 2007
84. Kitajima Y et al: Internalization of the 180 kDa bullous pemphigoid antigen as immune complexes in basal keratinocytes: An important early event in blister formation in bullous pemphigoid. *Br J Dermatol* **138**(1):71, 1998
85. Hall RP, 3rd et al: Rabbits immunized with a peptide encoded for by the 230-kD bullous pemphigoid antigen cDNA develop an enhanced inflammatory response to UVB irradiation: A potential animal model for bullous pemphigoid. *J Invest Dermatol* **101**(1):9, 1993
86. Kiss M et al: Experimental bullous pemphigoid generated in mice with an antigenic epitope of the human hemidesmosomal protein BP230. *J Autoimmun* **24**(1):1, 2005
87. Budinger L et al: Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. *J Clin Invest* **102**(12):2082, 1998
88. Leyendeckers H et al: Memory B cells specific for the NC16A domain of the 180 kDa bullous pemphigoid autoantigen can be detected in peripheral blood of bullous pemphigoid patients and induced in vitro to synthesize autoantibodies. *J Invest Dermatol* **120**(3):372, 2003
89. Lin MS et al: Epitopes targeted by bullous pemphigoid T lymphocytes and autoantibodies map to the same sites on the bullous pemphigoid 180 ectodomain. *J Invest Dermatol* **115**(6):955, 2000
90. Balding SD et al: Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. *J Invest Dermatol* **106**(1):141, 1996
91. Bernard P et al: The major cicatricial pemphigoid antigen is a 180-kD protein that shows immunologic cross-reactivities with the bullous pemphigoid antigen. *J Invest Dermatol* **99**(2):174, 1992
92. Jordan RE et al: The immunopathology of herpes gestationis. Immunofluorescence studies and characterization of "HG factor". *J Clin Invest* **57**(6):1426, 1976
93. Katz SI, Hertz KC, Yaoita H: Herpes gestationis. Immunopathology and characterization of the HG factor. *J Clin Invest* **57**(6):1434, 1976
94. Lin MS et al: Identification and characterization of epitopes recognized by T lymphocytes and autoantibodies from patients with herpes gestationis. *J Immunol* **162**(8):4991, 1999
95. Murakami H et al: Analysis of antigens targeted by circulating IgG and IgA autoantibodies in 50 patients with cicatricial pemphigoid. *J Dermatol Sci* **17**(1):39, 1998
96. Provost TT, Tomasi TB, Jr.: Evidence for complement activation via the alternate pathway in skin diseases, I. Herpes gestationis, systemic lupus erythematosus, and bullous pemphigoid. *J Clin Invest* **52**(7):1779, 1973
97. Shornick JK et al: Herpes gestationis: Clinical and histologic features of twenty-eight cases. *J Am Acad Dermatol* **8**(2):214, 1983
98. Tamada Y et al: Lichen planus pemphigoides: Identification of 180 kd hemidesmosome antigen. *J Am Acad Dermatol* **32**(5 Pt 2):883, 1995
99. Zone JJ et al: Identification of the cutaneous basement membrane zone antigen and isolation of antibody in linear immunoglobulin A bullous dermatosis. *J Clin Invest* **85**(3):812, 1990

100. Zone JJ et al: The 97 kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180 kDa bullous pemphigoid antigen, BPAg2. *J Invest Dermatol* **110**(3):207, 1998
101. Cram DL, Fukuyama K: Immunohistochemistry of ultraviolet-induced pemphigus and pemphigoid lesions. *Arch Dermatol* **106**(6):819, 1972
102. Mul VE et al: Radiation-induced bullous pemphigoid: A systematic review of an unusual radiation side effect. *Radiother Oncol* **82**(1):5, 2007
103. Thomsen K, Schmidt H: PUVA-induced bullous pemphigoid. *Br J Dermatol* **95**(5):568, 1976
104. Bastuji-Garin S et al: Drugs associated with bullous pemphigoid. A case-control study. *Arch Dermatol* **132**(3):272, 1996
105. Bordignon M et al: Bullous pemphigoid during long-term TNF-alpha blocker therapy. *Dermatology* **219**(4):357, 2009
106. Duong TA et al: Efalizumab-induced bullous pemphigoid. *J Am Acad Dermatol* **62**(1):161, 2010
107. Lee JJ, Downham TF, 2nd: Furosemide-induced bullous pemphigoid: Case report and review of literature. *J Drugs Dermatol* **5**(6):562, 2006
108. Monnier-Murina K et al: Bullous pemphigoid occurring during efalizumab treatment for psoriasis: A paradoxical auto-immune reaction? *Dermatology* **219**(1):89, 2009
109. Popadic S, Skiljevic D, Medenica L: Bullous pemphigoid induced by penicillamine in a patient with Wilson disease. *Am J Clin Dermatol* **10**(1):36, 2009
110. Lever WF: *Pemphigus and Pemphigoid*. Springfield, Illinois, 1965
111. Yancey KB, Egan CA: Pemphigoid: Clinical, histologic, immunopathologic, and therapeutic considerations. *JAMA* **284**(3):350, 2000
112. Sun C, Chang B, Gu H: Non-bullous lesions as the first manifestation of bullous pemphigoid: A retrospective analysis of 24 cases. *J Dermatolog Treat* **20**(4):233, 2009
113. Person JR, Rogers RS, 3rd: Bullous and cicatricial pemphigoid. Clinical, histopathologic, and immunopathologic correlations. *Mayo Clin Proc* **52**(1):54, 1977
114. Sollecito TP, Parisi E: Mucous membrane pemphigoid. *Dent Clin North Am* **49**(1):91, 2005
115. Venning VA et al: Mucosal involvement in bullous and cicatricial pemphigoid. A clinical and immunopathological study. *Br J Dermatol* **118**(1):7, 1988
116. Monkemüller K, Neumann H, Fry LC: Esophageal blebs and blisters. *Gastroenterology* **138**(2):e3, 2010
117. Nagashima R et al: Endoscopic hemostasis of hemorrhage from esophageal bullous pemphigoid. *Gastrointest Endosc* **52**(3):433, 2000
118. Provost TT et al: Unusual subepidermal bullous diseases with immunologic features of bullous pemphigoid. *Arch Dermatol* **115**(2):156, 1979
119. Borradori L et al: Localized pretibial pemphigoid and pemphigoid nodularis. *J Am Acad Dermatol* **27**(5 Pt 2):863, 1992
120. Person JR, Rogers RS, 3rd, Perry HO: Localized pemphigoid. *Br J Dermatol* **95**(5):531, 1976
121. Domloge-Hultsch N et al: Autoantibodies from patients with localized and generalized bullous pemphigoid immunoprecipitate the same 230-kd keratinocyte antigen. *Arch Dermatol* **126**(10):1337, 1990
122. Nemeth AJ et al: Childhood bullous pemphigoid. Clinical and immunologic features, treatment, and prognosis. *Arch Dermatol* **127**(3):378, 1991
123. Farrell AM et al: Childhood vulval pemphigoid: A clinical and immunopathological study of five patients. *Br J Dermatol* **140**(2):308, 1999
124. Schumann H et al: A child with localized vulval pemphigoid and IgG autoantibodies targeting the C-terminus of collagen XVII/BP180. *Br J Dermatol* **140**(6):1133, 1999
125. Calikoglu E et al: Localized bullous pemphigoid as an unusual complication of radiation therapy. *J Eur Acad Dermatol Venereol* **16**(6):646, 2002
126. Hafejee A, Coulson IH: Localized bullous pemphigoid 20 years after split skin grafting. *Clin Exp Dermatol* **30**(2):187, 2005
127. Macfarlane AW, Verbov JL: Trauma-induced bullous pemphigoid. *Clin Exp Dermatol* **14**(3):245, 1989
128. Massa MC, Freeark RJ, Kang JS: Localized bullous pemphigoid occurring in a surgical wound. *Dermatol Nurs* **8**(2):101, 1996
129. Melani L et al: Radiation therapy as a trigger factor for initially localized bullous pemphigoid. *Breast J* **11**(6):485, 2005
130. Ohata C et al: Localized bullous pemphigoid after radiation therapy: Two cases. *Acta Derm Venereol* **77**(2):157, 1997
131. Pardo J et al: Localized bullous pemphigoid overlying a fistula for hemodialysis. *J Am Acad Dermatol* **51**(2 Suppl):S131, 2004

132. Torchia D et al: Bullous pemphigoid initially localized around a urostomy. *Int J Dermatol* 45(11):1387, 2006
133. Vande Maele DM, Reilly JC: Bullous pemphigoid at colostomy site: Report of a case. *Dis Colon Rectum* 40(3):370, 1997
134. Amato L et al: Erythrodermic bullous pemphigoid. *Int J Dermatol* 40(5):343, 2001
135. Chan LS et al: Pemphigoid vegetans represents a bullous pemphigoid variant. Patient's IgG autoantibodies identify the major bullous pemphigoid antigen. *J Am Acad Dermatol* 28(2 Pt 2):331, 1993
136. Kim J et al: Pemphigoid vegetans: A case report and review of the literature. *J Cutan Pathol* 35(12):1144, 2008
137. Kim YJ et al: Dyshidrosiform bullous pemphigoid. *Acta Derm Venereol* 84(3):253, 2004
138. Korman NJ, Woods SG: Erythrodermic bullous pemphigoid is a clinical variant of bullous pemphigoid. *Br J Dermatol* 133(6):967, 1995
139. Scrivener Y et al: Erythrodermic bullous pemphigoid. *J Am Acad Dermatol* 41(4):658, 1999
140. Sugimura C et al: Dyshidrosiform pemphigoid: Report of a case. *J Dermatol* 30(7):525, 2003
141. Tashiro H et al: Pemphigoid nodularis: Two case studies and analysis of autoantibodies before and after the development of generalized blistering. *J Nippon Med Sch* 72(1):60, 2005
142. Yasuda M, Miyachi Y, Utani A: Two cases of dyshidrosiform pemphigoid with different presentations. *Clin Exp Dermatol* 34(5):e151, 2009
143. Demircay Z, Baykal C, Demirkesen C: Lichen planus pemphigoides: Report of two cases. *Int J Dermatol* 40(12):757, 2001
144. Hsu S, Ghohestani RF, Uitto J: Lichen planus pemphigoides with IgG autoantibodies to the 180 kd bullous pemphigoid antigen (type XVII collagen). *J Am Acad Dermatol* 42(1 Pt 1):136, 2000
145. Maceyko RF et al: Oral and cutaneous lichen planus pemphigoides. *J Am Acad Dermatol* 27(5 Pt 2):889, 1992
146. Stingl G, Holubar K: Coexistence of lichen planus and bullous pemphigoid. A immunopathological study. *Br J Dermatol* 93(3):313, 1975
147. Callen JP: Internal disorders associated with bullous disease of the skin. A critical review. *J Am Acad Dermatol* 3(2):107, 1980
148. Cassano N et al: Pemphigus vulgaris with circulating anti-desmoglein 3 and anti-BP180 antibodies: A case report and brief review of cases with coexistence of pemphigus vulgaris and bullous pemphigoid. *J Biol Regul Homeost Agents* 23(3):197, 2009
149. Ishiko A et al: Combined features of pemphigus foliaceus and bullous pemphigoid: Immunoblot and immunoelectron microscopic studies. *Arch Dermatol* 131(6):732, 1995
150. Leibovici V et al: Coexistence of pemphigus and bullous pemphigoid. *Int J Dermatol* 28(4):259, 1989
151. Cordel N et al: Neurological disorders in patients with bullous pemphigoid. *Dermatology* 215(3):187, 2007
152. Jedlickova H et al: Bullous pemphigoid and internal diseases – A case-control study. *Eur J Dermatol* 20(1):96, 2010
153. Stinco G et al: A retrospective epidemiological study on the association of bullous pemphigoid and neurological diseases. *Acta Derm Venereol* 85(2):136, 2005
154. Ly A et al: Anti-laminin 5 pemphigoid and acquired haemophilia. *Br J Dermatol* 146(6):1104, 2002
155. Patel RS et al: Acquired haemophilia heralded by bleeding into the oral mucosa in a patient with bullous pemphigoid, rheumatoid arthritis, and vitiligo. *Postgrad Med J* 82(963):e3, 2006
156. Zhang GS et al: Characterization of an acquired factor VIII inhibitor and plasmapheresis therapy in a patient with bullous pemphigoid. *Thromb Haemost* 96(5):692, 2006
157. Lindelof B et al: Pemphigoid and cancer. *Arch Dermatol* 126(1):66, 1990
158. Stone SP, Schroeter AL: Bullous pemphigoid and associated malignant neoplasms. *Arch Dermatol* 111(8):991, 1975
159. Venning VA, Wojnarowska F: The association of bullous pemphigoid and malignant disease: A case control study. *Br J Dermatol* 123(4):439, 1990
160. Hodge L et al: Bullous pemphigoid: The frequency of mucosal involvement and concurrent malignancy related to indirect immunofluorescence findings. *Br J Dermatol* 105(1):65, 1981
161. Arbesman CE et al: IgE levels in sera of patients with pemphigus or bullous pemphigoid. *Arch Dermatol* 110(3):378, 1974
162. Hadi SM et al: Clinical, histological and immunological studies in 50 patients with bullous pemphigoid. *Dermatologica* 176(1):6, 1988
163. Bushkell LL, Jordon RE: Bullous pemphigoid: A cause of peripheral blood eosinophilia. *J Am Acad Dermatol* 8(5):648, 1983

164. Crotty C, Pittelkow M, Muller SA: Eosinophilic spongiosis: A clinicopathologic review of seventy-one cases. *J Am Acad Dermatol* **8**(3):337, 1983
165. Lever WF: Pemphigus and pemphigoid. A review of the advances made since 1964. *J Am Acad Dermatol* **1**(1):2, 1979
166. Ahmed AR, Maize JC, Provost TT: Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy. *Arch Dermatol* **113**(8):1043, 1977
167. Beutner EH, Jordon RE, Chorzeliski TP: The immunopathology of pemphigus and bullous pemphigoid. *J Invest Dermatol* **51**(2):63, 1968
168. Fairley JA, Fu CL, Giudice GJ: Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid. *J Invest Dermatol* **125**(3):467, 2005
169. Parodi A, Rebora A: Serum IgE antibodies bind to the epidermal side of the basement membrane zone splits in bullous pemphigoid. *Br J Dermatol* **126**(5):526, 1992
170. Gammon WR et al: Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin. *J Invest Dermatol* **82**(2):139, 1984
171. Kelly SE, Wojnarowska F: The use of chemically split tissue in the detection of circulating anti-basement membrane zone antibodies in bullous pemphigoid and cicatricial pemphigoid. *Br J Dermatol* **118**(1):31, 1988
172. Sams WM, Jr., Jordon RE: Correlation of pemphigoid and pemphigus antibody titres with activity of disease. *Br J Dermatol* **84**(1):7, 1971
173. Ishiura N et al: Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid. *J Dermatol Sci* **49**(2):153, 2008
174. Iwata Y et al: Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. *Arch Dermatol* **144**(1):41, 2008
175. Messingham KA et al: A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid. *J Immunol Methods* **346**(1-2):18, 2009
176. Woodley DT: The role of IgE anti-basement membrane zone autoantibodies in bullous pemphigoid. *Arch Dermatol* **143**(2):249, 2007
177. Wieland CN et al: Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects. *Arch Dermatol* **146**(1):21, 2010
178. Gammon WR, Inman AO, 3rd, Wheeler CE, Jr.: Differences in complement-dependent chemotactic activity generated by bullous pemphigoid and epidermolysis bullosa acquisita immune complexes: Demonstration by leukocytic attachment and organ culture methods. *J Invest Dermatol* **83**(1):57, 1984
179. Gammon WR et al: Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. *J Am Acad Dermatol* **22**(4):664, 1990
180. Karpati S et al: In situ localization of IgG in epidermolysis bullosa acquisita by immunogold technique. *J Am Acad Dermatol* **26**(5 Pt 1):726, 1992
181. Venning VA, Wojnarowska F: Lack of predictive factors for the clinical course of bullous pemphigoid. *J Am Acad Dermatol* **26**(4):585, 1992
182. Bernard P et al: Risk factors for relapse in patients with bullous pemphigoid in clinical remission: A multicenter, prospective, cohort study. *Arch Dermatol* **145**(5):537, 2009
183. Joly P et al: Prediction of survival for patients with bullous pemphigoid: A prospective study. *Arch Dermatol* **141**(6):691, 2005
184. Roujeau JC et al: High risk of death in elderly patients with extensive bullous pemphigoid. *Arch Dermatol* **134**(4):465, 1998
185. Rzany B et al: Risk factors for lethal outcome in patients with bullous pemphigoid: Low serum albumin level, high dosage of glucocorticosteroids, and old age. *Arch Dermatol* **138**(7):903, 2002
186. Tanaka M et al: Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles. *Clin Exp Dermatol* **21**(1):23, 1996
187. Bystryń JC, Rudolph JL: Why is the mortality of bullous pemphigoid greater in Europe than in the US? *J Invest Dermatol* **124**(3):xx, 2005
188. Colbert RL et al: Mortality rate of bullous pemphigoid in a US medical center. *J Invest Dermatol* **122**(5):1091, 2004
189. Joly P et al: A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. *N Engl J Med* **346**(5):321, 2002
190. Parker SR et al: Mortality of bullous pemphigoid: An evaluation of 223 patients and comparison with the mortality in the general population in the United States. *J Am Acad Dermatol* **59**(4):582, 2008

191. Risser J, Lewis K, Weinstock MA: Mortality of bullous skin disorders from 1979 through 2002 in the United States. *Arch Dermatol* **145**(9):1005, 2009
192. Fine JD: Management of acquired bullous skin diseases. *N Engl J Med* **333**(22):1475, 1995
193. Chu J, Bradley M, Marinkovich MP: Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoid. *Arch Dermatol* **139**(6):813, 2003
194. Chuh AA: The application of topical tacrolimus in vesicular pemphigoid. *Br J Dermatol* **150**(3):622, 2004
195. Ko MJ, Chu CY: Topical tacrolimus therapy for localized bullous pemphigoid. *Br J Dermatol* **149**(5):1079, 2003
196. Lebeau S et al: Localized childhood vulvar pemphigoid treated with tacrolimus ointment. *Dermatology* **208**(3):273, 2004
197. Patton T, Korman NJ: Bullous pemphigoid treatment review. *Expert Opin Pharmacother* **7**(17):2403, 2006
198. Wojnarowska F et al: Guidelines for the management of bullous pemphigoid. *Br J Dermatol* **147**(2):214, 2002
199. Bystryj JC, Wainwright BD, Shupack JL: Oral and topical corticosteroids in bullous pemphigoid. *N Engl J Med* **347**(2):143, 2002
200. Savin JA: The events leading to the death of patients with pemphigus and pemphigoid. *Br J Dermatol* **101**(5):521, 1979
201. Khumalo NP et al: A systematic review of treatments for bullous pemphigoid. *Arch Dermatol* **138**(3):385, 2002
202. Bohm M et al: Bullous pemphigoid treated with mycophenolate mofetil. *Lancet* **349**(9051):541, 1997
203. Burton JL et al: Azathioprine plus prednisone in treatment of pemphigoid. *Br Med J* **2**(6146):1190, 1978
204. Guillaume JC et al: Controlled trial of azathioprine and plasma exchange in addition to prednisone in the treatment of bullous pemphigoid. *Arch Dermatol* **129**(1):49, 1993
205. Gurcan HM, Ahmed AR: Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. *Br J Dermatol* **161**(4):723, 2009
206. Heilborn JD et al: Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. *J Am Acad Dermatol* **40**(5 Pt 1):741, 1999
207. Kjellman P, Eriksson H, Berg P: A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. *Arch Dermatol* **144**(5):612, 2008
208. Nousari HC, Griffin WA, Anhalt GJ: Successful therapy for bullous pemphigoid with mycophenolate mofetil. *J Am Acad Dermatol* **39**(3):497, 1998
209. Paul MA, Jorizzo JL, Fleischer AB, Jr., White WL: Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. *J Am Acad Dermatol* **31**(4):620, 1994
210. Siegel J, Eaglstein WH: High-dose methylprednisolone in the treatment of bullous pemphigoid. *Arch Dermatol* **120**(9):1157, 1984
211. Bouscarat F et al: Treatment of bullous pemphigoid with dapsone: Retrospective study of thirty-six cases. *J Am Acad Dermatol* **34**(4):683, 1996
212. Person JR, Rogers RS, 3rd: Bullous pemphigoid responding to sulfapyridine and the sulfones. *Arch Dermatol* **113**(5):610, 1977
213. Venning VA, Millard PR, Wojnarowska F: Dapsone as first line therapy for bullous pemphigoid. *Br J Dermatol* **120**(1):83, 1989
214. Berk MA, Lorincz AL: The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report. *Arch Dermatol* **122**(6):670, 1986
215. Fivenson DP et al: Nicotinamide and tetracycline therapy of bullous pemphigoid. *Arch Dermatol* **130**(6):753, 1994
216. Kolbach DN et al: Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. *Br J Dermatol* **133**(1):88, 1995
217. Roujeau JC et al: Plasma exchange in bullous pemphigoid. *Lancet* **2**(8401):486, 1984
218. Ahmed AR: Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. *J Am Acad Dermatol* **45**(6):825, 2001
219. Ahmed AR, Dahl MV: Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. *Arch Dermatol* **139**(8):1051, 2003
220. Engineer L, Ahmed AR: Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: Analysis of current data. *J Am Acad Dermatol* **44**(1):83, 2001
221. Bara C et al: Methotrexate for bullous pemphigoid: Preliminary study. *Arch Dermatol* **139**(11):1506, 2003

222. Nousari HC, Anhalt GJ: Bullous pemphigoid treated with leflunomide: A novel immunomodulatory agent. *Arch Dermatol* **136**(10):1204, 2000
223. Milligan A, Hutchinson PE: The use of chlorambucil in the treatment of bullous pemphigoid. *J Am Acad Dermatol* **22**(5 Pt 1):796, 1990

